Juan V. Llau

Prof. Dr. Juan V. Llau


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
SKSibylle A. Kozek-Langenecker
Sibylle A. Kozek-Langenecker
AAArash Afshari
Arash Afshari
PAPierre Albaladejo
Pierre Albaladejo
CACesar Aldecoa
Cesar Aldecoa
EREdoardo De Robertis
Edoardo De Robertis
PWPiet Wyffels
Piet Wyffels
The aims of severe perioperative bleeding management are three-fold. First, preoperative identification by anamesis and laboratory testing of those patients for whom the perioperative bleeding risk may be increased. Second, implementation of strategies for correcting preoperative anaemia and stabilisation of the macro- and microcirculations in order to optimise the patient's tolerance to bleeding. Third, targeted procoagulant interventions to reduce the amount of bleeding, morbidity, mortality and costs. The purpose of these guidelines is to provide an overview of current knowledge on the subject with an assessment of the quality of the evidence in order to allow anaesthetists throughout Europe to integrate this knowledge into daily patient care wherever possible. The Guidelines Committee of the European Society of Anaesthesiology (ESA) formed a task force with members of scientific subcommittees and individual expert members of the ESA. Electronic databases were searched without language restrictions from the year 2000 until 2012. These searches produced 20 664 abstracts. Relevant systematic reviews with meta-analyses, randomised controlled trials, cohort studies, case-control studies and cross-sectional surveys were selected. At the suggestion of the ESA Guideline Committee, the Scottish Intercollegiate Guidelines Network (SIGN) grading system was initially used to assess the level of evidence and to grade recommendations. During the process of guideline development, the official position of the ESA changed to favour the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This report includes general recommendations as well as specific recommendations in various fields of surgical interventions. The final draft guideline was posted on the ESA website for four weeks and the link was sent to all ESA members. Comments were collated and the guidelines amended as appropriate. When the final draft was complete, the Guidelines Committee and ESA Board ratified the guidelines.

1 December 2010 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
WGWiebke Gogarten
Wiebke Gogarten
EVErik Vandermeulen
Erik Vandermeulen
HAHugo Van Aken
Hugo Van Aken
SKSibylle Kozek
Sibylle Kozek
JLJuan V. Llau
Juan V. Llau
CSCharles M Samama
Charles M Samama
Performing neuraxial anaesthesia in patients receiving antithrombotic drugs is controversial due to the increased risk of spinal epidural haematoma. Strict adherence to the recommended time intervals between the administration of anticoagulants, neuraxial blockade and the removal of catheters is thought to improve patient safety and reduce the risk of haematoma. Appropriate guidelines have been prepared by a number of national societies of anaesthesiologists, but they do not have universal acceptance. The introduction of new anticoagulants together with recent reports of stent thrombosis in patients with perioperative cessation of antiplatelet drugs have considerably broadened the issue and made revision necessary. To overcome deficiencies in content and applicability, the European Society of Anaesthesiology has taken the initiative to provide current and comprehensive guidelines for the continent as a whole. extensive review of the literature. in order to minimise bleeding complications during regional anaesthetic techniques, care should be taken to avoid traumatic puncture. If a bloody tap occurs when intraoperative anticoagulation is planned, postponing surgery should be considered. Alternatively, catheters can be placed the night before surgery. Regional anaesthesia in patients receiving full anticoagulation treatment continues to be contraindicated. Catheter manipulation and removal carry similar risks to insertion and the same criteria should apply. Appropriate neurological monitoring is essential during the postoperative recovery period and following catheter removal. The final decision to perform regional anaesthesia in patients receiving drugs that affect haemostasis has to be taken after careful assessment of individual risks and benefits.

1 January 2020 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
CACesar Aldecoa
Cesar Aldecoa
JLJuan V. Llau
Juan V. Llau
XNXavier Nuvials
Xavier Nuvials
Antonio ArtigasAntonio Artigas
Antonio Artigas
The endothelial glycocalyx comprises a complex layer of membrane-bound proteoglycans, secreted glycosaminoglycans, glycoproteins, glycolipids and bound plasma proteins such as albumin and antithrombin associated with the endothelial surface. The glycocalyx plays an important role in vascular homeostasis, regulating vascular permeability and cell adhesion, and acts as a mechanosensor for hemodynamic shear stresses; it also has antithrombotic and anti-inflammatory functions. Plasma proteins such as albumin are physiologically bound within the glycocalyx, thus contributing to stability of the layer. Albumin is the major determinant of plasma colloid osmotic pressure. In addition, albumin transports sphingosine-1-phosphate which has protective endothelial effects, acts as a free radical scavenger, and has immunomodulatory and anti-inflammatory effects. This review examines the physiological function of the endothelial glycocalyx and the role of human albumin in preserving glycocalyx integrity and the microcirculation.

1 June 2013 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
GPGilles Pernod
Gilles Pernod
PAPierre Albaladejo
Pierre Albaladejo
AGAnne Godier
Anne Godier
CSCharles M. Samama
Charles M. Samama
SSSophie Susen
Sophie Susen
PSPierre SIE
Pierre SIE

1 December 2011 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
PSPierre SIE
Pierre SIE
CSCharles M. Samama
Charles M. Samama
AGAnne Godier
Anne Godier
NRNadia Rosencher
Nadia Rosencher
ASAnnick Steib
Annick Steib
PAPierre Albaladejo
Pierre Albaladejo

1 January 2012 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
RKReinhold Herr Kreutz
Reinhold Herr Kreutz
JLJuan V. Llau
Juan V. Llau
BNBo Norrving
Bo Norrving
SHSylvia Haas
Sylvia Haas
ATAlexander Turpie
Alexander Turpie
Summary: A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have shown considerable promise in large-scale, randomised clinical studies for the management of thromboembolic disorders, and have been approved for clinical use in specific indications. Rivaroxaban is licensed for the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery, the treatment of deep-vein thrombosis and prevention of recurrent venous thromboembolism, and for stroke prevention in patients with non-valvular atrial fibrillation. Based on the clinical trial data for rivaroxaban, feedback on its use in clinical practice and the authors’ experience with the use of rivaroxaban, practical guidance for the use of rivaroxaban in special patient populations and specific clinical situations is provided. Although most recommendations are in line with the European summary of product characteristics for the approved indications, additional and, in several areas, different recommendations are given based on review of the literature and the authors’ clinical experience.